Here is an audio only interview which works to fill in the blanks about the rise and fall of Theranos and Elizabeth Holmes, its CEO. Tap the image for the story.
The rise and fall of Elizabeth Holmes, who started Theranos when she was 19 and became the world’s youngest female billionaire before it all came crashing down
Elizabeth Holmes started Theranos at age 19 and became the world’s youngest female billionaire. But 15 years later, she was charged with massive fraud.
Leaked video shows Theranos employees playing the video game they created where you shoot at the reporter who exposed the startup’s problems
Theranos’ employees blame the reporter who revealed that it was misleading people, so they created a game where you shoot at him. Now we have a video of it.
News teasers
Sample feeds – 
- New analysis links higher BMI to lower breast cancer risk for younger women
While obesity has been shown to increase breast cancer risk ... read more28 mins ago - MarketWatch.com: These companies’ drugs can boost your investment returns by reducing opioid abuse
Heron Therapeutics, Cara Therapeutics and Alkermes are discovering novel replacements ... read more4 hours ago - [Research Articles] Tissue engineering toward temporomandibular joint disc regenerationTreatments for temporomandibular joint (TMJ) disc thinning and perforation, conditions ... read more1 day ago
- Regulatory Convergence for Biologics through Capacity Building and TrainingSeveral regulatory convergence efforts for biologics are underway globally, with ... read more2 days ago
- Nano crystals impact stem cell fate during bone formationScientists from the University of Freiburg and the University of ... read more2 days ago
- The places where HIV shows no sign of ending, and the parts of the human brain that are bigger—in bigger brains
Nigeria, Russia, and Florida seem like an odd set, but ... read more7 days ago - Salmon teleconnection disservice... read more1 week ago
For all the feeds tap Headlines
Theranos lays off almost all of its remaining workers
Blood-testing firm Theranos Inc. laid off most of its remaining workforce in a last-ditch effort to preserve cash and avert or at least delay bankruptcy for a few more months, according people familiar with the matter.
Source: Theranos lays off almost all of its remaining workers
Meet Silicon Valley’s Answer to Martin Shkreli
Theranos was once a major player in the growing iiquid biopsy market.
Something went wrong and now CEO Elizabeth Holmes is in very serious trouble.
Continue below for more on this story.
Looking back… A couple of years ago we began following the liquid biopsy buzz and the massive interest several Silicon Valley investors had in firms like Theranos.
Now Theranos CEO and product evangelist Elizabeth Holmes is facing fraud charges arising from numerous deceptive practices, including her own false representations to media and investors alike.
So, what happened?
One good place to start is the September, 2016 Vanity Fair “HIVE” article written by investigative reporter Nick Bilton (tap Lizzy’s image).
CNBC recently broadcast new charges against the likeable Ms. Holmes. Tap the broadcast image for a video.
More posts below and tap Lizzy once again to access the 4/2017 WSJ article that quoted an investor as having said that “… Theranos used a shell company to buy commercial lab equipment, then pretended it was using its own technology in demonstrations for prospective partners and investors.”
The quote “Theranos didn’t do their homework” is attributed to Harvard Business School Professor and CNBC contributor Bill George who discussed the Theranos issue on CNBC’s “Power Lunch” on their April 14, 2016 broadcast. For the discussion in its entirety tap on the Theranos signage.
Timeline note: By now, Creative Biotech had been following this cancer blood test ‘saga’ for weeks and you can read some of our coverage immediately below.
In april 2016, watchmojo.com published a countown of 10 points noted in the Theranos scandal. Tap the WM image for that video.
Unreliable cancer blood tests are in the news again.
PALO ALTO, Calif. – Embattled blood-testing company “Theranos” is once again facing scrutiny for its technology as a new study in the “Journal of Clinical Investigation” (first published 3-28-16) raises more questions about the accuracy of the company’s single-drop blood tests. Tap test tubes for more.
The testing was conducted by the Icahn School of Medicine at Mt. Sinai, which compared privately-held Theranos’ methods to more traditional testing methods of larger companies Quest Diagnostics (DGX) and Laboratory Corporation of America Holdings (LH).
The above article was written by By Alex Keown, BioSpace.com Breaking News Staff. Tap their logo for entire story.
Theranos isn’t alone in avoiding regulation using an easily exploited loophole — in fact, it’s just one among many. Pathway Genomics (see story below), Admera Health, and Strand Life Sciences are diagnostics companies that offer cancer tests that impact people’s health care decisions. Each of these companies has been making use of what’s known as the “laboratory developed test” loophole — which makes avoiding pre-market verification downright easy.
Pathway Genomics raised $40 million in its last funding round and claims to have a very simple, inexpensive blood test that can tell if someone who otherwise appears normal and healthy might indeed have cancer. Here follows a piece we published earlier on this subject.
Pathway first caused a collective eyebrow to be raised at CBS last September, when they announced the launch of a test they were calling the “CancerIntercept Detect and Monitor”.
Additional notoriety came their way when Pathway and their screening tool were the subject of a discussion on an episode of “Keeping Up With the Kardashians” – Order a kit for $299 and problem solved – now back to shopping.
Pathway’s Board features some very powerful people, like Peter Pace, the former Chairman of the Joint Chiefs of Staff, Barbara Franklin, former Secretary of Commerce and Newt Gingrich, former Presidential candidate – no influential lightweights here.
The liquid biopsy market is expected to be well in excess of $22 billion by the year 2020 and in truth this product may be just as many years away from complete development. The CBS scrutiny caused the firm to pull back on its promotions and you can view the entire broadcast and story text by clicking the CBS logo above.
Learn about genomes courtesy of the National Human Genome Research Institute by clicking on this image.